
educationFeb 26, 202443:10pending
Author Interview: Professor Andrew Cope, Professor Paul Emery and Professor John Issacs
About this episode
Join Professor Peter Nash from the Griffith University in Brisbane, as well as Professors Andrew Cope, Professor of Rheumatology and Head of the Centre for Rheumatic Diseases at Kings College London, Professor Paul Emery, Clinical Professor and Director of the Leeds Biomedical Research Centre, and Professor John Isaacs, Professor of clinical immunology and Director of Newcastle Biomedicine Versus Arthritis Experimental Arthritis Treatment Centre.
Together they discuss the recent paper ‘Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial’, published in The Lancet on 13th February 2024.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum

Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
The IMID Forum
Apr 14, 202616:32failed

Author Interview: Professor Helena Marzo-Ortega, March 2026
The IMID Forum
Apr 9, 202637:39failed

Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi pre...
The IMID Forum
Mar 26, 202610:02failed

Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeuti...
The IMID Forum
Mar 19, 202633:29failed